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INTRODUCTION
Both the newly available powerful immunosuppressive
agents and the steady increase of the number of organ trans-
plantion have increased the incidence of posttransplantation
lymphoproliferative disorders (PTLDs) in recent years. Most
PTLDs are B-cell derived and are closely linked to Epstein-
Barr virus (EBV). It is estimated that 14% of PTLDs are of
T-cell origin and over 60 cases of posttransplant T-cell malig-
nancies have been reported so far (1-3). The most common
type of PTLDs of T-cell origin is peripheral T-cell lymphoma,
and in contrast to the B-cell PTLDs, the association with EBV
is less constant in posttransplant T-cell lymphomas. We here-
in present the clinical, histological, immunophenotypic, and
molecular features of a focal Ki-1-positive, anaplastic large
cell lymphoma kinase (ALK)-negative T-cell lymphoma that
occurred in a patient receiving long-term immunosuppres-
sive therapy after renal transplantation.
CASE REPORT
A 47-yr-old male patient received a cadaveric renal trans-
plant in July 1991 at the age of 40 yr for chronic renal failure
of 10 yr. His immunosuppression regimen consisted of aza-
thioprine, prednisolone, and oral cyclosporine. In May 1997,
splenomegaly was noted on ultrasonography. In January 1998,
he presented with a general ache, mild fever, recurrent para-
nasal sinusitis, and enlargement of multiple right cervical
lymph nodes which measured up to 1.5 cm in diameter.
Physical examination revealed enlarged tonsils with a whitish
plaque. A computerized tomography scan revealed numer-
ous enlarged bilateral cervical lymph nodes and variable-sized
multiple masses in the spleen without definite abnormality
in the liver. A cervical node biopsy was performed and the
diagnosis of a malignant T-cell lymphoma was made. The
dosage of cyclosporine was adjusted by monitoring the whole
blood cyclosporine level and was in the range of 125 ng/mL.
He received whole neck radiation therapy with 4.14 Gy
from January 1998 to February 1998. Laboratory studies
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Epstein-Barr Virus-Associated Peripheral T-Cell Lymphoma involving
Spleen in a Renal Transplant Patient
The incidence of posttransplantation lymphoproliferative disorders (PTLDs) has
increased in recent years. Although rare, various types of T-cell lymphoma have
been reported and their association with Epstein-Barr virus (EBV) has been com-
pared with B-cell PTLDs. We report a case of splenic peripheral T-cell lymphoma
occurring in a 47-yr-old male patient 7 yr after renal allograft transplantation. The
spleen showed sinusoidal proliferation of focal CD30 positive, large, atypical lym-
phoid cells. Positivity for CD3 and cytolytic granule-associated proteins was also
demonstrated in the tumor cells, while anaplastic large cell lymphoma kinase
(ALK) and CD8 were not expressed. Strong nuclear signals for EBV mRNA were
noted by EBER1 in situ hybridization. A molecular genetic study demonstrated a
rearrangement of the gamma T-cell receptor gene. To our knowledge, this case
is unique in terms of a posttransplant T-cell lymphoma that shows focal CD30,
cytolytic granule-associated proteins, and EBV positivity.
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showed the followings; hemoglobin, 9.0 g/dL; hematocrit,
25%; WBC count, 1.2×109/L; and platelet count, 6×109/L.
Examination of peripheral blood smear showed microangio-
pathic hemolytic anemia; burr cells, helmet cells, along with
immature granulocyte precursors and toxic granules of mature
granulocytes. Bone marrow biopsy showed occasional hemo-
phagocytic histiocytes without atypical lymphocytes. Results
of the serologic study for virus were as follows: Epstein-Barr
virus viral capsid antigen (VCA)  IgG: >1:160, VCA IgM:
negative, EBNA: positive, EBV DNA PCR: positive, EBV
early antigen (EA)-DR IgG: positive, EA-DR IgA: negative,
and EA-DR IgM: positive. There were a diffuse pattern of
EA-D both in the nucleus and cytoplasm and a restricted
pattern of EA-R in the cytoplasm. Other viral test were cyto-
megalovirus IgG/IgM (+/-), herpes virus IgM: negative,
hepatitis C virus antibody: negative, human immunodefi-
ciency virus antibody: negative, and anti-platelet antibody:
negative. In May 1998, a diagnostic and therapeutic splenec-
tomy was performed because of a diagnostic impression of
thrombotic thrombocytopenic purpura. After splenectomy,
he suffered a postoperative intracerebral hemorrhage and
died. Autopsy was not performed.
Methods of Laboratory Investigations
Routine morpholoic studies were done on 4- m tissue
sections fixed in formalin, and stained with hematoxylin and
eosin. Immunohistochemical studies were performed on for-
malin-fixed, paraffin-embedded sections of the spleen using
a labeled streptavidin-biotin method (Universal LSAB kit,
DAKO, Carpinteria, CA, U.S.A.). All antibodies were ob-
tained from commercial sources. The primary antibodies were
CD3, CD20, CD30, CD43, CD45RO, CD68, ALK (Dako,
Carpinteria, CA, U.S.A.), CD4, CD5, CD8, CD56, granzyme
B (Novocastra, Newcastle-upon-Tyne, U.K.), TIA-1 (Im-
munotech, Miami, FL, U.S.A.), and TCR / (T cell Diag-
nostics, Cambridge, MA, U.S.A.). We performed the in situ
hybridization to detect and localize EBV genomes using a
biotinylated 30-base oligonucleotide probe complementary
to a portion of the EBER1 gene, which is a gene of the EBV
genome that is actively transcribed (up to 107 copies/cell) in
latently infected cells.
Serologic tests for IgG and IgM antibodies to EBV-VCA
(BION, Illinois, U.S.A.), EBNA (BION, Illinois, U.S.A.)
and IgG, IgA, and IgM antibodies to EBV EADR (Granbio,
California, U.S.A.) were performed by immunofluorescent
antibody assay. The patient’s blood was screened for EBV
DNA using the Bam W primers and 35 cycles of PCR
amplification. The sequences of the primers and probe used
were as follows:
TC60 primer: CCAGAGGTAAGTGGACTT
TC61 primer: GACCGGTGCCTTCTTAGG
TC62 probe:  TTCTGCTAAGCCCAAC
For genotyping, DNA was extracted from the paraffin-
embedded spleen. The V and J regions of the TCR- chain
primer were used for TCR- gene rearrangement amplifica-
tion using GeneAmp 9600 (4). Nested PCR was first per-
formed with VA and JA primers and the second round was
performed with V and J primers. The PCR products were
denatured and then renatured on ice for 20 min. The prod-
ucts were eletrophoresed on a 15% polyacrylamide gel at 12℃
and developed with silver staining. The sequences of primers
for TCR (5′ �3′ ) were as follows:
VA : 5′ -GAAGCTTCTAGCTTTCCTGTCTC-3′
JA : 5′ -CGTCGACAACAAGTGTTGTTCCAC-3′
V:  5 ′ -AGGGTTGTGTTGGAATCAGG-3′
J:  5 ′ -CGTCGACAACAAGTGTTGTTCCAC-3′
Pathologic findings
The cervical lymph node showed diffuse effacement of the
structure by medium-sized lymphocytes having irregular
nuclear outlines as well as immunoblasts (Fig. 1). The atypical
lymphoid cells demonstrated positivity for CD3 and TIA-1,
focal positivity for CD30, and negative reaction to CD20 and
CD79a on the immunohistochemical study. The spleen mea-
sured 20×10×5 cm and weighed 550 g. Cut sections re-
vealed multifocal, poorly defined pinkish-brown nodular mass-
es measuring up to 7 cm in diameter (Fig. 2). Histologic sec-
tions of the spleen revealed a diffuse red pulp infiltrate of
large lymphoid cells with a near-total effacement of the white
pulp structure. The tumor tissue was diffusely infiltrated by
large-sized lymphoid cells with irregular, often multilobated
vesicular nuclei with one or more prominent nucleoli and ex-
tensive pale to basophilic cytoplasms (Fig. 3A). Mitotic figures
were frequently encountered. In the congested red pulp, there
were also numerous banal-looking histiocytes showing hemo-
phagocytosis (Fig. 3B). The large atypical lymphoid cells
demonstrated an aberrant T-cell immunophenotype (CD3+,
CD4 ‐ , CD5 ‐ , CD8 ‐ , CD43+, and CD45RO+) in the
immunohistochemical studies. The tumor cells demonstrated
cytoplasmic positivity for TIA-1, CD30, and granzyme B
(Fig. 4). Neither ALK nor TCR  / expression was observed.
The hybridization signal for the EBV EBER1 RNA probe was
detected in more than 95% of the large atypical neoplastic
cells in both cervical lymph node and the spleen (Fig. 5).
PCR DNA analysis using the splenic tissue showed a clonal
rearrangement of the TCR- chain gene (Fig. 6). DNA study
and immunostain of the lymph nodes were not done.
DISCUSSION
PTLDs are a heterogenous group of lymphoid proliferative
disorders that are distinguished by specific histological, phe-
notypic, and genotypic features. Non-Hodgkin’s lymphoma
is the most common lymphoma that occurs in transplant
recipients (TRs) accounting for 21% of all malignant neo-274 H.K. Lee, H.J. Kim, E.H. Lee, et al.
plasias. Most of these lymphomas are classified as large-cell
lymphomas, the great majority of which are of the B-cell
type. However, non-B-cell lymphomas also occur in TRs,
with 14% being of T-cell origin (1-3). Like T-cell lymphomas
that occur in immunocompetent patients, the majority are
peripheral T-cell lymphomas, not otherwise specified. These
T-cell lineage lymphomas, like most peripheral T-cell lym-
phomas (PTCL), commonly have either a T-helper (CD4+) or
a T-cytotoxic (CD8+) phenotype and express the  / T-cell
receptor heterodimer. CD8 is more commonly expressed by
/ T cells, but CD8 can also be expressed by some  / T-
cell lymphomas. Interestingly, our patient showed a  chain
Fig. 1. Lymphoma cells are intermediate to large in size and have
oval-shaped nuclei with irregular contour, coarse chromatin, and
moderate amount of pale cytoplasm (H&E, ×200).
Fig. 2. Cut section of the spleen reveals multifocal ill-defined red-
brown nodular masses (arrows).
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Fig. 3. The splenic red pulp is diffusely infiltrated with an abnormal
population of lymphoid cells showing irregular large nuclei (A)
(H&E, ×200). Some histiocytes showed erythrophagocytosis (B)
(H&E, ×400).
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Fig. 4. Immunohistochemical demonstration of TIA-1 (A), CD30
(B), and granzyme B (C) in the tumor tissue (PAP, ×100).
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TCR gene rearrangement with an expression of TIA-1 and
granzyme B, indicating activated cytotoxic T-cells pheno-
type without definite immunoreactivity of CD8. Recently,
several studies have shown that the expression of these cyto-
toxic proteins in PTCL tumors is associated with an extran-
odal site, a T gamma delta-cell phenotype, CD30 expres-
sion, and anaplastic feature (5). Rothenberg et al. (6) men-
tioned an immune reaction of cytotoxic  T lymphocytes
in an EBV-induced PTLD. The cytotoxic T cells predomi-
nantly expressed  TCR rather than  TCR and mediated
non-major histocompatibility-restricted cytotoxicity against
EBV-infected cells. Under these circumstances, although we
can not apply this suggestion to our case definitely, we think
that the cytolytic granule-associated proteins may suggest
cytotoxic T lymphocyte differentiation in spite of the nega-
tive immunoreactivity of CD8. Also, EBV is known to induce
the CD30 expression in EBV-transformed cell lines; there-
fore EBV-associated posttransplant lymphomas may prove
to be CD30+.
As differential diagnosis, we considered the possibility of
anaplastic large cell lymphoma (ALCL) and  hepatosplenic
T-cell lymphoma. Ki-1-positive ALCL is a subtype of PTCLs
showing CD30 immunoreactivity and only a few cases of
Ki-1-positive B-cell lymphoma have been reported as PTLD.
However, with the focal CD30 expression, it might be im-
proper to diagnose the present patient as ALCL without
showing ALK positivity. We also considered the possibility
of  hepatosplenic T-cell lymphoma. The findings of the
chain TCR gene rearrangement, the expression of TIA-1,
and the negative reactions for both CD4 and CD8 have been
described but a positive expression of CD30 and granzyme
B are not features of  hepatosplenic T-cell lymphoma. 
Lymphoproliferative disorders occurring in association with
immunosuppression are unique. Of concern is the role of EBV
in the pathogenesis of these EBV-associated PTLDs. Com-
pared with B-cell PTLDs, T-cell PTLDs show a looser asso-
ciation with EBV and more often monoclonality. EBV infec-
tion was believed to be limited to B lymphocytes, follicular
cells of lymph nodes and tonsils, and epithelial cells of the
pharynx and cervix. B lymphocytes are known to be infected
via the C3d receptor (CD21), which is expressed constantly
in benign and malignant B cells. However, recent reports
have shown that CD21 and EBV may be present in some
malignant T-cells. Medeiros et al. (7) suggested that EBV
may be involved in the transformation of low grade T cells
proliferation to high grade lesions, and Huh et al. (8) described
the high incidence of EBV in peripheral T cell lymphomas
in Koreans. However, the exact mechanism of how the EBV
get into the T-cells is still unclear. Because most B-cell PTLDs
are primary EBV infections, a lack of previous EBV infection
is a risk factor of B-cell PTLDs. Conversely, chronic EBV
infection was assumed to be the cause of EBV-associated T-
cell lymphoma in the previous reports. All 10 cases of EBV-
associated T-cell lymphomas reported by Su et al. (9). had
evidence of previous infection, and none of them had an ele-
vated level of IgM class anti-VCA. In our patient, IgM and
IgG EA-DR were positive. This suggests reactivation of a
past EBV infection. We could not find a report of T-cell PTLD
with IgM positivity in the literature. 
Clinically, at the time of diagnosis, most of the T-cell PTLD
cases had fully developed T-cell malignant neoplasms. The
long-term survival of patients with T-cell PTLD is generally
poor, as was shown in the present case and in others. Most
of the patients died within 1 yr from the diagnosis. In view
of high mortality rate of this lymphoma, early diagnosis is
critical to the patients’ outcome. 
Fig. 5. Diffuse positivity for EBV on in situ hybridization using the
EBV EBER1 RNA probe (×100).
Fig. 6. Polymerase chain reaction (PCR) analysis for T-cell recep-
tor V-gamma-J-gamma reveal a clonal V-gamma-J-gamma rear-
rangement (lane T). Lane N is the negative control and lane P is
the positive control.
PT N276 H.K. Lee, H.J. Kim, E.H. Lee, et al.
To our knowledge, this is the first case report of a post-
transplant T-cell lymphoma involving spleen, which is asso-
ciated with EBV positivity, gamma TCR gene rearrangement,
cytolytic granule-associated proteins, and CD30 positivity.
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